Flash glucose monitoring (FGM) : A clinical review on glycaemic outcomes and impact on quality of life
Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved..
Flash glucose monitoring (FGM) is widely accepted as an alternative means to conventional finger prick test for measuring glucose level in individuals with diabetes mellitus. In this clinical review, we endeavour to draw all available clinical evidence on the usage and efficacy of FGM from research trials and observational studies in real-world settings. We aim to explore its clinical efficacy and impact on quality of life (QoL) in the diabetic population. In terms of clinical outcomes, use of FGM is associated with a significant reduction in glycated haemoglobin A1c (HbA1c) level, notably in patients with suboptimal glycaemic control prior to commencement of FGM and reduction in time spent in hypoglycaemia. FGM demonstrated non-inferiority in device accuracy when compared to other well-established CGMs available in the market. Patients have reported improved QoL and treatment satisfaction measured by validated objective scores after consistent use of FGM. This results in a positive impact on patient psychosocial wellbeing and ultimately enhances patient compliance and optimisation of glycaemic control. Evaluation of QoL and patient reported outcome measures (PROMs) will require a standardised approach to allow comparability of the results and evidence.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Journal of diabetes and its complications - 34(2020), 6 vom: 15. Juni, Seite 107559 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ang, Eshen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 05.10.2021 Date Revised 05.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jdiacomp.2020.107559 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306822741 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306822741 | ||
| 003 | DE-627 | ||
| 005 | 20231225124222.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jdiacomp.2020.107559 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1022.xml |
| 035 | |a (DE-627)NLM306822741 | ||
| 035 | |a (NLM)32089428 | ||
| 035 | |a (PII)S1056-8727(19)31341-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ang, Eshen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Flash glucose monitoring (FGM) |b A clinical review on glycaemic outcomes and impact on quality of life |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2021 | ||
| 500 | |a Date Revised 05.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Flash glucose monitoring (FGM) is widely accepted as an alternative means to conventional finger prick test for measuring glucose level in individuals with diabetes mellitus. In this clinical review, we endeavour to draw all available clinical evidence on the usage and efficacy of FGM from research trials and observational studies in real-world settings. We aim to explore its clinical efficacy and impact on quality of life (QoL) in the diabetic population. In terms of clinical outcomes, use of FGM is associated with a significant reduction in glycated haemoglobin A1c (HbA1c) level, notably in patients with suboptimal glycaemic control prior to commencement of FGM and reduction in time spent in hypoglycaemia. FGM demonstrated non-inferiority in device accuracy when compared to other well-established CGMs available in the market. Patients have reported improved QoL and treatment satisfaction measured by validated objective scores after consistent use of FGM. This results in a positive impact on patient psychosocial wellbeing and ultimately enhances patient compliance and optimisation of glycaemic control. Evaluation of QoL and patient reported outcome measures (PROMs) will require a standardised approach to allow comparability of the results and evidence | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Flash glucose monitoring | |
| 650 | 4 | |a FreeStyle Libre | |
| 650 | 4 | |a Patient-reported outcome measure | |
| 650 | 4 | |a Quality of life | |
| 650 | 4 | |a Type 1 diabetes mellitus | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a Lee, Zong Xuan |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Sacha |e verfasserin |4 aut | |
| 700 | 1 | |a Nana, Melanie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of diabetes and its complications |d 1997 |g 34(2020), 6 vom: 15. Juni, Seite 107559 |w (DE-627)NLM012632503 |x 1873-460X |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:6 |g day:15 |g month:06 |g pages:107559 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jdiacomp.2020.107559 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2020 |e 6 |b 15 |c 06 |h 107559 | ||